Top Markets
#1 Islamic Coin Islamic Coin +152.25%
#2 Bitway Bitway +40.84%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +38.17%
#4 Starpower Starpower +29.00%
#5 Pleasing Gold Pleasing Gold +28.64%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.29%
#7 Pons Pons +22.64%
#8 aelf aelf +18.42%
#9 Decred Decred +14.29%
#10 Venom Venom +14.02%
Coin of the day
Islamic Coin Islamic Coin
설정
언어
한국어
통화
USD
테마
Proteomics International Laboratories Ltd. Proteomics International Laboratories Ltd.

Proteomics International Laboratories Ltd.

PIQ
주식 순위 #30008
Proteomics International Laboratories Ltd operates as a medical technology... Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.
주가
$0.11284557
시가총액
$18.66M
변동 (1일)
3.23%
변동 (1년)
-47.82%
국가
AU
거래 Proteomics International Laboratories Ltd. (PIQ)

카테고리

Healthcare
Proteomics International Laboratories Ltd. (PIQ)의 P/E 비율
2026 기준 P/E 비율 TTM: 0
Proteomics International Laboratories Ltd.의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 0입니다. 2026년 말 기준 P/E 비율은 0였습니다.
Proteomics International Laboratories Ltd.의 P/E 비율 기록 (2026 ~ 2026)
매년 말 P/E 비율
연도 P/E 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/E 비율
회사 P/E 비율 P/E 비율 차이 국가
HCA Healthcare, Inc. HCA Healthcare, Inc.
HCA Healthcare, Inc.
HCA.US
 13.51 -
US
Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA
FRE.DE
 - -
DE
Dr. Sulaiman Al Habib Medical Services Group Company Dr. Sulaiman Al Habib Medical Services Group Company
Dr. Sulaiman Al Habib Medical Services Group Company
4013.SR
 33.05 -
SA
Tenet Healthcare Corporation Tenet Healthcare Corporation
Tenet Healthcare Corporation
THC.US
 10.26 -
US
IHH Healthcare Berhad IHH Healthcare Berhad
IHH Healthcare Berhad
5225.KL
 - -
MY
P/E 비율 읽는 방법

P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.

P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.

양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.